Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-15,300
Closed -$3.31M – 91
2026
Q2
$3.31M Hold
15,300
– – 0.76% 25
2026
Q1
$2.8M Hold
15,300
– – 0.67% 24
2025
Q4
$2.69M Hold
15,300
– – 0.65% 25
2025
Q3
$2.14M Hold
15,300
– – 0.49% 52
2025
Q2
$1.92M Buy
15,300
+3,504
+30% +$437K 0.43% 46
2025
Q1
$1.61M Sell
11,796
-4,504
-28% -$644K 0.34% 70
2024
Q4
$2.49M Buy
16,300
+150
+0.9% +$25.3K 0.48% 64
2024
Q3
$3.13M Buy
+16,150
New +$3.38M 0.58% 54
2021
Q4
– Sell
-8,100
Closed -$2.29M – 94
2021
Q3
$2.29M Hold
8,100
– – 0.33% 89
2021
Q2
$2.8M Sell
8,100
-11,500
-59% -$3.48M 0.37% 88
2021
Q1
$5.48M Buy
19,600
+10,700
+120% +$2.89M 0.7% 37
2020
Q4
$2.18M Hold
8,900
– – 0.31% 95
2020
Q3
$2.52M Hold
8,900
– – 0.41% 78
2020
Q2
$2.38M Sell
8,900
-4,600
-34% -$1.38M 0.42% 80
2020
Q1
$4.27M Hold
13,500
– – 0.87% 25
2019
Q4
$4.01M Hold
13,500
– – 0.61% 44
2019
Q3
$3.14M Hold
13,500
– – 0.52% 57
2019
Q2
$3.16M Hold
13,500
– – 0.5% 64
2019
Q1
$3.19M Hold
13,500
– – 0.49% 72
2018
Q4
$4.06M Hold
13,500
– – 0.65% 31
2018
Q3
$4.77M Hold
13,500
– – 0.72% 28
2018
Q2
$3.92M Buy
+13,500
New +$3.8M 0.59% 40

Other funds holding BIIB

Clark Estates's BIIB Position: Q3 2026 in Review

Clark Estates sold out of Biogen (BIIB) in Q3 2026, closing a stake of 15,300 shares — an estimated $3.31M sold.

Clark Estates first reported a position in BIIB in Q2 2018 and held it in 22 quarters. The position peaked at $5.48M in Q1 2021. 881 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Clark Estates reported no remaining Biogen position as of Q3 2026 after selling out during the quarter.
  • Clark Estates sold 15,300 Biogen shares in Q3 2026, an estimated $3.31M.
  • Clark Estates first reported a position in Biogen in Q2 2018 and held it in 22 quarters.
  • Clark Estates's Biogen position peaked at $5.48M in Q1 2021.
  • 881 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Clark Estates's 13F filing for Q3 2026, filed 10 Nov 2026.